CClinicalTrials.gg
CompletedNCT04171050Updated Jun 3, 2025Results posted

Pudendal Enhancement of Enhanced Recovery After Surgery (ERAS) for Reconstructive Surgery (PEERS)

A Phase 4 interventional study of Local anaesthetic and Pudendal Nerve Block plus anesthesia in Pain Management, sponsored by University of California, Los Angeles. Completed at 1 site in United States. Open to female participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by University of California, Los Angeles · Phase 4, Interventional, and Supportive care

Phase
Phase 4
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
Female
01

Study summary

Patients will undergo their vaginal reconstructive surgery in the usual manner, but will also be randomly assigned on the day of surgery to either receive the extra injection of numbing medication at the onset of surgery or not. The chances they will be assigned to the additional injection is 50%. Their care in the hospital and after surgery will be the same. They will participate in the study for a total of 6 weeks during which time they will be asked to complete two phone surveys, during which a provider will check in on pain level and pain medication use, and one office visit at 6 weeks. The office visit is part of their routine care and would be a scheduled visit regardless if they participated in the study or not. If they are unable to return to the office for a postoperative visit at 6 weeks, they will be contact by phone instead to obtain information on satisfaction with postoperative care, any complications after surgery, and overall how they are doing after surgery.

Read the detailed description

PROTOCOL SUMMARY AND/OR SCHEMA

To determine whether administration of a PNB at time of vaginal reconstructive surgery can reduce use of narcotics and reported pain scores in the immediate postoperative period within the setting of multimodal postoperative pain control of ERAS. Women >18yo undergoing vaginal reconstructive surgery without a hysterectomy will be randomized to either standard of care with typical use of local anesthetic during their surgery versus perioperative PNB in addition to typical use of local anesthetic during their surgery. PNB will be performed with 0.5% bupivacaine and 10cc will be injected bilaterally. All patients will be on a standard preoperative and postoperative multimodal pain regimen. Patients will be followed until 6 weeks after surgery.

OVERVIEW OF STUDY DESIGN/INTERVENTION

This will be a prospective blinded randomized controlled trial. We will recruit women who are undergoing vaginal prolapse repair surgery with a Female Pelvic Medicine and Reconstructive Surgery fellowship-trained provider within the UCLA Health System. Women will be recruited prior to undergoing vaginal reconstructive surgery. They will then be randomized to control group with standard of care with local anesthesia used during surgery (Group 1) or PNB in addition to use of local anesthesia typically used during surgery (Group 2).

All pain medication will be standardized. Preoperative medications per our ERAS protocol will include oral acetaminophen 1000mg, gabapentin 600mg, and celecoxib 400mg. During surgery the patient will undergo their randomized intervention as either Group 1 or Group 2. Postoperative medications per our ERAS protocol including scheduled acetaminophen 1,000mg PO every 6 hours and ketorolac 30mg IV every 6 hours. For supplemental pain medication patients will have the following available: tramadol 50mg PO every 6 hours as needed for moderate pain (pain 4-6/10 on NRS scale), tramadol 100mg PO every 6 hours as needed for severe pain (pain 7-10/10 on NRS scale), and oxycodone 5mg PO every 4 hours as needed for breakthrough pain as supplemental pain medication. If the above regimen does not allow for sufficient pain control then additional hydromorphone IV 0.2mg or morphine IV 2mg can be ordered by the provider as needed, but will not be standard in the postoperative order set. The providers will know what intervention the patients underwent, but the patients and the care team obtaining pain scores in the hospital will be blinded to the intervention.

The patients' pain scores on the numeric rating scale (NRS) and supplemental opioid use measured in morphine milligram equivalent (MME) will be tracked during their hospitalization, which is typically a 23-hour observation. They will then be called at 48 hours for further follow-up on pain score by NRS and asked how much opioid medication they have taken since leaving the hospital and their overall satisfaction with their pain control. To help with the determination of supplemental pain medication used and pain scores, the patients will be provided a worksheet upon discharge that outlines their recommended medication routine, allows them to record their supplemental opioid medication use with dose and time, and also provides space for them to record their pain score at 48 hours post operatively. The patient will then be contacted at 2 weeks after surgery to determine if they have returned to normal activities (walking, sitting, and performing daily household tasks comfortably) and if so at what point this occurred, as well as their overall satisfaction with their postoperative pain control again. The two week contact will be either a phone call or clinic visit depending on the provider's preference for patient follow-up. The last point of contact will be at 6 weeks to determine time to return to normal activities, if they had not met this milestone at the 2-week contact, and again assess their overall satisfaction with their postoperative pain control. If a patient is discharge same day instead of admitted for 23-hour observation they will also receive a call at 24 hours postoperative to check on pain score and supplemental pain medication used.

02

Conditions studied

  • Pain Management

Keywords

  • Pain Management
  • Pudendal Nerve Block (PNB)
  • Vaginal Reconstruction
03

In context

Lead sponsor

University of California, Los Angeles is the lead sponsor of 1,142 studies on the registry; 192 are open to participants now.

Of its 91 completed or terminated interventional studies of FDA-regulated products, 66 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Female
  • Age > 18 years old
  • English speaking
  • Undergoing vaginal reconstructive surgery of at least 2 compartments (anterior vaginal wall, posterior vaginal wall, and/or apical suspension including hysteropexy, uterosacral ligament suspension, or sacrospinous ligament fixation)

Exclusion criteria

Exclusion Criteria:

  • Hysterectomy at time of surgery-is variable in duration which may affect response to PNB
  • Inability to tolerate opioids-allergy or medical contraindication
  • Inability to tolerate local anesthetic agents-allergy or medical contraindication
  • Inability to tolerate NSAIDS-allergy or medical contraindication
  • Inability to tolerate acetaminophen-allergy or medical contraindication
  • Coagulation disorder
  • Chronic pain syndrome using opioid medication on a regular basis prior to surgery
05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
44 participants (actual)

Study arms

  • Active comparator
    Group 1: Local Anesthesia

    Standard of care with local anesthesia used during surgery

    Drug: Local anaesthetic

  • Active comparator
    Group 2: Local Anesthesia plus Pudendal Nerve Block

    Pudendal Nerve Block (PNB) in addition to local anesthesia used during surgery

    Drug: Pudendal Nerve Block plus anesthesia

Interventions

  • DrugLocal anaesthetic

    Local anesthesia injections

  • DrugPudendal Nerve Block plus anesthesia

    Local anesthesia injections plus a pudendal nerve block

06

What researchers measure

Primary outcomes

  1. Narcotic Use

    Measured in morphine milligram equivalents (MME) at 24 hours

    Time frame: 24 hours after surgery

  2. Narcotic Use

    Measured in MME at 48 hours

    Time frame: 48 hours after surgery

Secondary outcomes

  1. Pain Scores

    Average pain score by Numerical Rating Scale (NRS). The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain).

    Time frame: 0-2 hours, 2-4 hours, 4-8 hours, 8-12 hours, 24 hours, and 48 hours after surgery

  2. Return to Normal Daily Activities

    Days to return to normal activity, defined as walking, sitting, and performing daily household tasks comfortably. Upon discharge, all participants received a diary to record the date they returned to normal daily activities. Participants were contacted at 2 and 6 weeks postoperatively either by telephone or during their scheduled office visit and were asked about their time to return to normal activity.

    Time frame: 6 weeks after surgery

  3. Patient Satisfaction With Postoperative Recovery

    Satisfaction with postoperative pain control was assessed using a verbal scale of 1=very satisfied, 2=Somewhat satisfied, 3=Neither satisfied nor dissatisfied, 4=Somewhat dissatisfied, 5=very dissatisfied

    Time frame: 48 hours after surgery, 2 weeks after surgery

  4. Length of Hospital Stay

    Tracked in hours

    Time frame: Tracked by hour through time of patient discharge (up to 72 hours)

07

Results

Posted Jun 3, 2025

Participant flow

Participant flow — Overall Study
MilestoneGroup 1: Local AnesthesiaGroup 2: Local Anesthesia Plus Pudendal Nerve Block
Started2222
Completed2121
Not completed11

Outcome measures

PrimaryNarcotic Use

Measured in morphine milligram equivalents (MME) at 24 hours

Time frame:
24 hours after surgery
Reported as:
Median · MME
Narcotic Use
MMEGroup 1: Local AnesthesiaGroup 2: Local Anesthesia Plus Pudendal Nerve Block
Narcotic Use8 (0 to 20)6.75 (0 to 15)
PrimaryNarcotic Use

Measured in MME at 48 hours

Time frame:
48 hours after surgery
Reported as:
Median · MME
Narcotic Use
MMEGroup 1: Local AnesthesiaGroup 2: Local Anesthesia Plus Pudendal Nerve Block
Narcotic Use8 (0 to 26)7 (0 to 35)
SecondaryPain Scores

Average pain score by Numerical Rating Scale (NRS). The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain).

Time frame:
0-2 hours, 2-4 hours, 4-8 hours, 8-12 hours, 24 hours, and 48 hours after surgery
Reported as:
Mean · score on a scale
Pain Scores
score on a scaleGroup 1: Local AnesthesiaGroup 2: Local Anesthesia Plus Pudendal Nerve Block
0-2 hours1.2 ± 1.81.6 ± 2.4
2-4 hours1.4 ± 1.71.1 ± 1.8
4-8 hours1.9 ± 1.81.4 ± 2.0
24 hours4 ± 23 ± 3
48 hours3 ± 24 ± 3
SecondaryReturn to Normal Daily Activities

Days to return to normal activity, defined as walking, sitting, and performing daily household tasks comfortably. Upon discharge, all participants received a diary to record the date they returned to normal daily activities. Participants were contacted at 2 and 6 weeks postoperatively either by telephone or during their scheduled office visit and were asked about their time to return to normal activity.

Time frame:
6 weeks after surgery
Reported as:
Median · Days
Return to Normal Daily Activities
DaysGroup 1: Local AnesthesiaGroup 2: Local Anesthesia Plus Pudendal Nerve Block
Return to Normal Daily Activities10 (6 to 18)10 (7 to 11)
SecondaryPatient Satisfaction With Postoperative Recovery

Satisfaction with postoperative pain control was assessed using a verbal scale of 1=very satisfied, 2=Somewhat satisfied, 3=Neither satisfied nor dissatisfied, 4=Somewhat dissatisfied, 5=very dissatisfied

Time frame:
48 hours after surgery, 2 weeks after surgery
Reported as:
Count of participants · Participants
Patient Satisfaction With Postoperative Recovery
ParticipantsGroup 1: Local AnesthesiaGroup 2: Local Anesthesia Plus Pudendal Nerve Block
1 - at 48 hours1613
2 - at 48 hours34
3 - at 48 hours01
4 - at 48 hours02
5 - at 48 hours10
Not obtained at 48 hours11
1 - at 2 weeks1517
2 - at 2 weeks02
3 - at 2 weeks20
4 - at 2 weeks01
5 - at 2 weeks21
Not obtained at 2 weeks20
SecondaryLength of Hospital Stay

Tracked in hours

Time frame:
Tracked by hour through time of patient discharge (up to 72 hours)
Reported as:
Median · Hours
Length of Hospital Stay
HoursGroup 1: Local AnesthesiaGroup 2: Local Anesthesia Plus Pudendal Nerve Block
Length of Hospital Stay16.5 (4.5 to 24)9 (5 to 23)

Adverse events

Collected over 6 weeks postoperatively. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Local Anesthesia0/22 (0%)0/22 (0%)6/22 (27.3%)
Group 2: Local Anesthesia Plus Pudendal Nerve Block0/22 (0%)1/22 (4.5%)7/22 (31.8%)
Most frequent serious events
Most frequent serious events
EventGroup 1: Local AnesthesiaGroup 2: Local Anesthesia Plus Pudendal Nerve Block
hospital readmissionGeneral disorders0/221/22
Most frequent other events
Most frequent other events
EventGroup 1: Local AnesthesiaGroup 2: Local Anesthesia Plus Pudendal Nerve Block
Urinary retention at 48hrRenal and urinary disorders4/226/22
Pudendal nerve entrapmentSurgical and medical procedures0/221/22
Postoperative nauseaGeneral disorders1/220/22
Anesthetic complicationInjury, poisoning and procedural complications1/220/22

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group 1: Local AnesthesiaGroup 2: Local Anesthesia Plus Pudendal Nerve BlockTotal
Median63 (59 to 69)66 (53 to 70)65 (58 to 69)
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Local AnesthesiaGroup 2: Local Anesthesia Plus Pudendal Nerve BlockTotal
Female222244
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group 1: Local AnesthesiaGroup 2: Local Anesthesia Plus Pudendal Nerve BlockTotal
White181634
Black000
Asian123
Other123
Refused to answer224
Region of Enrollment
Region of Enrollment(participants)Group 1: Local AnesthesiaGroup 2: Local Anesthesia Plus Pudendal Nerve BlockTotal
United States222244
08

Study locations

1 site
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · May 30, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04171050
Lead sponsor
University of California, Los Angeles
Responsible party
Tamara Grisales (Principal Investigator, University of California, Los Angeles) — Principal investigator
First posted
Nov 20, 2019
Start date
Nov 14, 2019
Primary completion
Aug 28, 2023
Completion
Aug 28, 2023
Results posted
Jun 3, 2025
Last update
Jun 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion